Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0267964 (
PAA
)
2,561
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the feasibility and efficacy of target thrombolysis with recombinant
tissue plasminogen activator
(rtPA) covalently bound to magnetic nanoparticle (MNP) and retained to the target site in vivo by an external magnet. Polyacrylic acid-coated magnetite (
PAA
-MNP, 246 nm) was synthesized and characterized; rtPA was immobilized to
PAA
-MNP through carbodiimide-mediated amide bond formation. The enzyme activities of the bound rtPA, as measured by a chromogenic substrate assay and (125)I-fibrinolysis assay, were 87+/-1% and 86+/-3% of that of free rtPA. Under guidance with the magnet moving back and forth along the iliac artery, the thrombolytic activity of
PAA
-MNP-rtPA with rtPA equivalent to 0.2mg/kg was determined by flowmetry in a rat embolic model. Intra-arterial administration of
PAA
-MNP-rtPA restored the iliac blood flow within 75 min to 82% of that before the clot lodging, whereas equivalent amount of
PAA
-MNP or free rtPA exerted no improvement on hemodynamics. At the end of 2-h period,
PAA
-MNP-rtPA did not alter levels of hemoglobin, hematocrit, or blood cell count. In conclusion, immobilization of rtPA to
PAA
-MNP with covalent binding resulted in a stable rtPA preparation and predictable amount of rtPA around the target site under magnetic guidance; this approach may achieve reproducible and effective target thrombolysis with <20% of a regular dose of rtPA.
...
PMID:Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. 1929 10